Are you Dr. Renschler?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 35 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
300 Pasteur Dr
Stanford, CA 94305Phone+1 650-723-4000
Summary
- Dr. Markus Renschler, MD is an oncologist in Stanford, California. He is currently licensed to practice medicine in California. He is affiliated with Stanford Health Care.
Education & Training
Stanford Health Care-Sponsored Stanford UniversityInternship, Internal Medicine, 1988 - 1989
Stanford University School of MedicineClass of 1988
Certifications & Licensure
CA State Medical License 1989 - 2026
Clinical Trials
- Radiation Therapy Plus Gadolinium Texaphyrin in Treating Patients With Brain Metastases Start of enrollment: 1998 Aug 01
- Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced Cancer Start of enrollment: 2002 Feb 01
- AMR PH GL 2007 CL001 Phase 3 Trial in Patients With Small Cell Lung Cancer After Failure of First-Line Chemotherapy Start of enrollment: 2007 Sep 01
- Join now to see all
Publications & Presentations
PubMed
- 56 citationsA randomized, controlled phase III trial of nab-Paclitaxel versus dacarbazine in chemotherapy-naïve patients with metastatic melanomaEvan M. Hersh, M. Del Vecchio, Michael P. Brown, Richard F. Kefford, Carmen Loquai
Annals of Oncology. 2015-11-01 - 4444 citationsIncreased Survival in Pancreatic Cancer with nab-Paclitaxel plus GemcitabineDaniel D. Von Hoff, Thomas J. Ervin, Francis P. Arena, E. Gabriela Chiorean, Jeffrey R. Infante
The New England Journal of Medicine. 2013-10-30 - 210 citationsRELATIONSHIP BETWEEN NEUROCOGNITIVE FUNCTION AND QUALITY OF LIFE AFTER WHOLE-BRAIN RADIOTHERAPY IN PATIENTS WITH BRAIN METASTASISJing Li, Søren M. Bentzen, Jialiang Li, Markus F. Renschler, Minesh P. Mehta
International Journal of Radiation Oncology, Biology, Physics. 2008-05-01
Press Mentions
CYT-0851 Phase 1 Dose Escalation Results Show Early Clinical Activity and Generally Well Tolerated Safety Profile in Advanced Solid Tumors and Hematologic MalignanciesJune 5th, 2022- Cyteir Therapeutics Announces the Appointment of Dr. Jeffrey S. Humphrey to Board of DirectorsDecember 16th, 2021
- Cyteir Therapeutics Selected to Join Russell 2000® IndexSeptember 20th, 2021
- Join now to see all
